$0
bluebird & 2seventy to Split in October; Marcela Maus Appointed to 2seventy’s Board of Directors; bluebird Receives $75M in Private Equity Financing Before Separation
On Tuesday, September 7, bluebird bio announced (press release) that the separation of their oncology business (2seventy bio) is anticipated to occur in mid-October 2021. Additionally, bluebird appointed Marcela Maus to their Board of Directors. Upon the separation of the two companies, Maus will transition to 2seventy’s Board of Directors. Furthermore, on Wednesday, September 8, bluebird announced (press release) that they have secured an additional $75M in private placement equity financing. Below, Celltelligence provides insights on bluebird’s decision to split into two companies, while discussing how Maus could help 2seventy achieve their clinical development goals.